Stem cell transplantation for myelodysplasia.
Klingemann
H G
HG
Section of Bone Marrow Transplant and Cell Therapy, RUSH Cancer Institute, Chicago, IL, USA.
Deeg
H J
HJ
D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017710:Lymphocyte Transfusion; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D012720:Severity of Illness Index; D015996:Survival Rate; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous / Q000401:mortality; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents